Close

Press Releases

On 25 June 2018, Lonza, in collaboration with Kirkstall Ltd., a biotechnology company based in Rotherham (UK), is hosting a free 60-minute webinar on the development of more physiologically relevant 3D lung-immune cell models for enhanced disease modeling.

STA Pharmaceutical Co., Ltd. (WuXi STA), a subsidiary of WuXi AppTec, announces that its partner, Ascletis has received approval from China Food and Drug Administration (CFDA) of its Category 1 new drug, Ganovo® (also known as Danoprevir or ASC08), to treat viral hepatitis C.

Sustainable engineering is more than a buzzword in today’s industry 4.0. Zero leakage, the reduction of fugitive emissions and environmentally safe manufacturing have become top priorities for both end users and producers.

Powder containment and aseptic transfer valve specialist ChargePoint Technology continues its growth strategy within the German, Austrian, and Swiss regions with its recent appointment of a new regional business development manager, Patrick Werner.

Highly regulated manufacturing operations must control access to devices, applications and physical spaces to ensure data integrity, compliance and security without compromising productivity. Nymi is bringing a new innovative authentication solution to these operations with the Nymi Enterprise Edition.

The Wasdell Group (Wasdell), a leading outsourcing partner to companies within the pharmaceutical, medical device and clinical trials industries, is investing £500k in a new laboratory at its Newcastle site.

Progressive Care Inc , a personalized healthcare services and technology company, announced that the company has completed the installation of a TCGRx Automated Pouch Packaging System at its Miami-Dade County PharmCo location.

TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes.

P-MEC China will be held at the Shanghai New International Expo Center (SNIEC), Shanghai, China, from 20-22 June. The event is seen as an accurate gauge of industry growth potential, and features a large exhibition and several in-depth conferences.

The University Hospital Center (UHC) Zagreb brings 1.3 million patients to Clinerion’s network of hospitals, expanding its global footprint into Croatia.

Aptar Pharma, a leading provider of innovative drug delivery systems, and Propeller Health, a leading digital therapeutics company, announced plans to collaborate on the launch of a comprehensive platform to develop digital medicines for multiple therapeutic areas and diseases.

CRF Health, a leading global provider of patient-centered eSource technology and service solutions for the life sciences industry, announced that the company has been recognized as2018 New Entrant of the Year in Romania’s PIN Awards.

A new report by CPhI forecasts sizable changes ahead for the pharma markets in the Middle East and Africa over the next few years.

Pfizer Inc. announced the United States FDA approved RETACRIT® (epoetin alfa-epbx), a biosimilar to Epogen® and Procrit® (epoetin alfa)1, for all indications of the reference product. RETACRIT is now the first and only biosimilar erythropoiesis-stimulating agent (ESA) to be approved in the U.S.

Recipharm, the contract development and manufacturing organisation (CDMO), has established a dedicated taskforce to manage the potential impact of Brexit on its organisation.

Aptar Pharma, a leading drug delivery systems provider, is pleased to be exhibiting once again at CPhI China 2018, taking place from June 20-22 at the Shanghai New International Exhibition Center, Shanghai, China.

Lonza announced the addition of hepatic stellate cells, Kupffer cells and liver-derived endothelial cells to its extensive hepatocytes portfolio.

Cleveland Clinic and Brooks Automation. Inc. willlaunch a 21,000-square-foot biorepository in Cleveland’s Fairfax neighborhood to enhance researchers’ study of human tissue samples and advance personalized medicine for an array of conditions – including cancer, heart disease, and epilepsy.

Density of raw materials and finished products affects their quality and lifetime. A properly performed density determination analysis may be crucial to verify material characteristics.

UCB announced that the U.S. FDA has approved a supplemental new drug application (sNDA) for the company’s newest anti-epileptic drug BRIVIACT CV oral formulations indicated as monotherapy and adjunctive therapy in the treatment of partial onset (focal) seizures in patients age four years and older. 

Novartis announced that the US FDA has approved Gilenya® (fingolimod) for the treatment of children and adolescents 10 to less than 18 years of age with relapsing forms of multiple sclerosis (RMS), making it the first disease-modifying therapy indicated for these patients.

Powder containment and aseptic transfer valve specialist, ChargePoint Technology, has launched a unique Smart monitoring hub to support efficiency and safety within chemical and pharmaceutical manufacturing processes.

CRF Health, the leading provider of patient-centered eSource for the life sciences industry, announced that its electronic Clinical Outcome Assessment (eCOA) solutions have been selected for a significant insomnia trial by a European pharmaceutical company specializing in the discovery and development of small molecules.

STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec, announces that its active pharmaceutical ingredient (API) R&D and manufacturing facility located in Changzhou, China has secured Pre-Approval Inspection (PAI) for two APIs from the U.S. FDA – with no Form 483s issued. This is the first time that WuXi STA’s Changzhou facility has been inspected by the FDA.

Organised by HKTDC and co-organised by the Hong Kong Medical and Healthcare Device Industries Association, the ninth edition of the HKTDC Hong Kong International Medical Devices and Supplies Fair opened today and continues through 9 May at the Hong Kong Convention and Exhibition Centre.

The 8thInternational Trade Exhibition and Conference on Analytical Laboratory Equipment & Technology, Biotechnology & Life Sciences and Chemical & Safety will return again during 12th– 14thSeptember 2018 at EH102-103, BITEC, Thailand. 

On 16 May 2018, Lonza is hosting a free 60-minute webinar on innovative technologies for building advanced human liver culture platforms that better mimic common liver diseases, such as non-alcoholic fatty liver disease, liver fibrosis and hepatitis B viral infection.

Biogen and Neurimmune announced that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s Phase 3 investigational treatment for early Alzheimer’s disease.

The Asian Pharma IT Summit 2018 is a premium strategic platform for large pharma, biotech, leading research institutes and technology pioneers to explore the real world value and application of the most cutting-edge technology along the R&D pipeline.

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, announced key organizational changes within its biologics business to further align its organization with customer demand for integrated and comprehensive, end-to-end biologics solutions.

Messe Muenchen India organized a regional edition of analytica Anacon India and India Lab Expo, the market leading trade fairs for laboratory technology, analysis, biotechnology and diagnostics.

It was privilege for the team of World Pharma Today to interact with the officials of Nanning Sugar Industry Co. Ltd. at API China 2018.

Dotmatics Ltd, a leading provider of scientific informatics solutions and services, announced Bioregister 3.0, a major update to the company’s web-based system for registering and managing biological entities used in the development of novel biologic compounds.

Provepharm Life Solutions announces that ArchiMed and Téthys Invest have joined the company’s shareholder base as minority investors.

Codexis, Inc and Porton Pharma Solutions, Ltd announce a strategic collaboration to deploy Codexis’ world-leading biocatalyst technology within Porton’s global custom intermediate and active pharmaceutical ingredients (API) development and manufacturing business.

The Health Industry Summit (tHIS) 2018 hosted by Reed Sinopharm, opened in Shanghai at the National Exhibition and Convention Center on 11th April 2018. This is the largest gathering of healthcare industry professionals in the world with well over 200,000 attendees from more than 150 countries and regions and over 7,000 exhibitors.

The 6th annual conference will gather the growing freeze drying community, filled with industry thought leaders and principle scientists involved in: manufacturing, material sciences, bio-therapeutics and pharmaceutical engineering.

SMi are delighted to have interviewed our speaker Maxime Gaillot, Senior Device Engineer, Roche, for Injectable Drug Delivery!

TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, announced EU FMD Express – a cost-effective, simplified solution designed specifically to address the needs of smaller pharmaceutical companies complying with the EU Falsified Medicines Directive (FMD.)

Bio industry which is linked closely with pharmaceutical industry comes into the spotlight as new growth power in globally. KOREA PHARM recreate under the name of “Korea Int’l Pharmaceutical & bio-Pharma Exhibition”. 

AstraZeneca announced that the EC has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment of adults with hyperkalaemia.

Are you looking for new business partners, extendingyour distributor network or sourcing specific products on the Chinese pharma market?

GlaxoSmithKline plc  announces that it has reached an agreement with Novartis for the buyout of Novartis’ 36.5% stake in their Consumer Healthcare Joint Venture for $13 billion (£9.2 billion).

With Tuberculosis (TB) estimated to infect around 781 out of every 100 000 South Africans, people living with HIV/AIDS (PLHIV) are currently at the highest risk of both contracting and dying of this condition.

Bosch Packaging Technology pools knowledge with Bosch Center for Artificial Intelligence and Corporate Research.
Schopfheim / Frankfurt, Germany – At Achema, Bosch Packaging Technology presents its new data mining service, which has recently been added to the range of pharma services for solid dosage forms.
The service is offered by the Bosch subsidiary Hüttlin. The aim is to evaluate existing machine data more effectively to identify and eliminate root causes. “So far, about 50 percent of deviations have been classified as ‘human error’,” says Dr Marc Michaelis, expert for continuous production and process verification at Hüttlin. “Yet we assume that this is true for no more than ten percent. The rest is often misinterpreted due to missing information. As a matter of fact, there is already enough data available to get to the bottom of the causes. However, there is a lack of knowledge and time to read this data correctly.” First projects have shown that new patterns and failure causes can be defined and remedied in the production process thanks to data mining, and can help to achieve a more stable product quality in the long run.

 Correct interpretation of machine data
Thanks to Bosch’s data mining tool, it is now possible to examine large amounts of data for the smallest effects using statistical methods. In general, the data from two production batches is already sufficient to draw first conclusions. The more data is available for evaluation over a longer period, the more details can be identified. All it takes is machine sensors, which already collect data on almost all historical machines, as well as the right tool to disclose the data. “Large investments are not required to use the existing data more effectively. The key to success lies in merging knowledge from different disciplines,” says Michaelis. “Bosch not only has the necessary technical expertise, but also extensive process knowledge in customers’ product manufacturing. To identify reasons for process deviations, which are not obvious at first sight, we teamed up with the statistics experts from our Bosch Center for Artificial Intelligence in Germany and the U.S. Together we will raise the data treasure.”

 

 

The potential of this approach has already been demonstrated successfully in different customer projects. For instance, when a customer suddenly produced a
“out of specification” (OOS) batch, the Bosch experts systematically got to the bottom of things. The recorded data showed that a particular valve wasresponsible for the deviation. However, the valve had been excluded beforehand since it was considered uncritical in terms of product quality. Thanks to the data analysis, deeper correlations and an undetected cascade of connections could be identified. “Eventually, we found out that the valve provided an indirect indication of a false gas flow in the system, which was not visible at first sight. The problem could then be easily solved by recalibrating the system,” Michaelis explains.

Maintaining consistently high quality Consistently high product quality is a critical factor in the pharmaceutical industry, since authorities such as the FDA and EMA have strict guidelines for process understanding, monitoring and validation. “To make successful root cause analyses and process improvements, or to develop a control strategy as part of continuous process verification, we offer customers our new data mining service,” Michaelis says. “We are looking forward to further projects to pursue the
path of industry 4.0 together with our customers.”



Cologne (DE) / Walkersville, MD (USA), 26 March 2018. On 24 April 2018, Lonza is hosting a free 60-minute webinar on what are the best practices for connecting and integrating devices and systems in QC and production and how can the data captured be used to make better, more informed decisions.

BioLIVE – the UBM bioprocessing and manufacturing event opening in October (9-11) in Madrid – announces that it is to build on the success of last year’s global small molecule country rankings by introducing a biologics manufacturing and processing league table.

At ACHEMA,the leading international trade fair for the process industries in June in Frankfurt am Main, market leading supplier of fluidizedbed and spouted bed systems, Glatt, will showcaseseveral new developments, including a compact system for continuous agglomeration and a modular control system that’s easy to customize.

The Tredegar facility is our development and manufacturing Center of Excellence with specialist expertise in the processing of highly potent molecules. The site has undergone significant investments over recent years; this latest project ensures analytical capacity and capability to service increasing customer demand.


The investment will see the laboratory increase its analyst headcount by approximately 60 percent and increase its High-Performance Liquid Chromatography (HPLC) capacity in excess of 20 percent, in addition to tripling its capacity for sample receipt. The layout design of the facility incorporates state-of-the-art Lean philosophies and optimized safety, combined with leading ergonomic principles, to deliver enhanced throughput and additional efficiency improvements.


Since launching the contained manufacturing facility, utilizing the latest in containment technology at Tredegar; the site has seen significant growth in its global customer base. This latest project will ensure that we are able to service both existing and potential new clients, as well as offering a project initiation in terms of analytical transfer within 4-6 weeks.


The site offers a true Center of Excellence for the development and manufacturing of pharmaceutical products in a variety of dosage forms and has over 30 years of experience in the specialist handling of potent molecules. Investment in state-of-the-art contained equipment, combined with the creation of a ‘Potent Passport’ philosophy to identify the specific handling requirements for every Highly Potent Active Pharmaceutical Ingredient (HPAPI) project, defines PCI as a market leader within this space. Contained technology includes Xcelodose® micro-dosing for early stage development drug-in-capsule (DIC), fluid bed granulation and roller compaction for products sensitive to heat and moisture.
Commenting on the expansion, PCI Senior Vice President, International, Richard Yarwood said: “Expansion of our laboratory services is an important program for the Tredegar site. Speed to market is of critical importance to our clients. We pride ourselves on continually improving our service for both existing and potential new clients and our analytical service is integral from the early stages of analytical development through to commercial launch and the associated annual stability testing.”
He continued “Among our many key strengths is our ability to on-board projects faster than our competitors. This additional footprint will ensure we are able to continue to offer this speed of project initiation addressing customer need.“

Micell® Technologies, Inc., a privately-held, development-stage biomedical company, today provided an update on its recently expanded intellectual property portfolio. With the granting of 24 patents in 2017, including eight that issued in the fourth quarter, Micell's extensive intellectual property portfolio comprises 186 patents (166 issued and 20 allowed) protecting the company's novel drug-eluting stent, its enabling technologies, and future biomedical and other applications.


Micell's technology platform uses unique surface modification and polymer science to allow for precisely and consistently controlled drug elution. This technology made possible the successful development of Micell's drug-eluting stent, the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent). The device is designed to optimize clinical performance and healing compared to other currently available drug-eluting coronary stents.


"Patents issued throughout the past year represent external validation of Micell's innovative approach to controlled drug delivery. Beyond MiStent, this platform technology potentially allows for diverse and broadly based biomedical applications that could address unmet clinical needs.

To date, there are more than 8,410 claims -- issued, allowed and pending -- associated with Micell's patents, and additional patent applications currently are pending," said Arthur J. Benvenuto, Micell's Chairman and CEO.
Editor's Note: For detailed information related to Micell's intellectual property portfolio, please contact Micell Technologies.

Envigo is investing in an expansion of its surgical facility at its Livermore, California site in response to large market demand from West Coast customers.

Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces that its next-generation sequencing (NGS)-based MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping Kit is now CE marked, enabling the Company to commercialize the device in Europe.

SMi Group are delighted to announce the 6thannual Pharmaceutical Freeze Drying Technology conference, being held this June 2018! Read on for a massive £400 off.

Drug Safety 2018 aims to discuss the latest findings and current thinking on pharmacovigilance. Importantly, it will address the newest regulatory updates and interpretations of them, including the impact of the vital and much awaited Clinical Trial Regulations.

Building on the success of SMi's 10th Annual Flagship Conference Pre-Filled Syringes, SMi are thrilled to present the launch of their Injectable Drug Delivery conference being held at Holiday Inn, Kensington Forum, London, on the 16th – 17th May 2018.

Novartis announced the launch of two new Joint Working Projects with National Cancer Vanguard sites, which aim to identify ways to improve cancer patient care pathways and access to services. The projects will be based at The Christie in Greater Manchester and within the UCLH Cancer Collaborative region (north and east London), covering a catchment population of 6.9 million people. The two projects are part of Novartis' ongoing commitment to combine resources, time, and expertise with the NHS, with the aim to significantly improve cancer patient outcomes.


With one in two people born after 1960 expected to develop cancer at some point in their lifetime[1], optimising working practices and addressing variations in care is essential to ensure the best outcomes for cancer patients. Central to both Joint Working Projects is the use of data analytics to generate insights, which will be used to improve cancer patients' experiences, one of the six key priorities of the NHS cancer strategy.


The Joint Working Project with UCLH Cancer Collaborative will adopt the use of Multi-Disciplinary Team (MDT) level balanced scorecards to capture service outcomes data for breast, lung, lymphoma, melanoma, and prostate cancer patient pathways. This service level data will include information on cancer patients' waiting times versus targets, the number of patients diagnosed with cancer, and the proportion of patients being prescribed chemotherapy and receiving it at home. Patient or clinical information will not be disclosed as part of the project.


Decisions on clinical practice are informed by data, however, information from these pathways is not currently captured under one source, and varies across different types of cancer and hospitals. The NHS and Novartis are jointly funding two project analysts to manage the project and to compare data from the MDT scorecards to service standards in the National Institute for Health and Care Excellence (NICE) treatment guidelines. Insights will be used by staff to improve MDTs' effectiveness and enhance patient care pathways, to develop care levels that are tailored to individual patient needs and provide a better quality of service for patients.
"Through the use of the MDT scorecards, we will be able to gather data on service outcomes across multiple cancers to identify areas for improvement," said Professor Kathy Pritchard-Jones, chief medical officer for UCLH Cancer Collaborative. "Reducing variations in cancer treatment pathways is vital to ensuring our patients receive the highest level of care we can provide them, regardless of the staging or type of cancer they have."


The Joint Working Project with The Christie NHS Foundation Trust will work to address care pathway inconsistencies in breast cancer, the most common cancer in the UK accounting for 31% of all new cancer diagnoses in women[3]. The project includes a partnership with IQVIA, a leading global provider of information and innovative technology solutions, to analyse current breast cancer pathways and identify opportunities to enhance care. This will involve examining relevant anonymised healthcare data including Public Health England's Cancer Analysis System (CAS) and NHS Hospital Episodic Statistics (HES) to establish the current state of the breast cancer treatment pathways across Greater Manchester so that variations in access to care can be better understood. The project will also evaluate patient journeys by enabling patients to record their experiences of treatment pathways through the use of innovative technology provided by the app, uMotif. It is anticipated that findings from the project will lead to improvements in the timeliness of treatment interventions for patients, and provide clarity on where to focus resource efforts, subsequently helping to address any variation in access to treatment.


"At The Christie we are committed to improving treatments and pathways for our patients, and this partnership will allow us to harness the power of data analytics to improve care for patients with secondary breast cancer," said Professor Andrew Wardley, clinical director of NIHR Manchester Clinical Research Facility at The Christie. "We are hopeful that the success in this project could lead to advancements in care for breast cancer patients across the country."


If the two initiatives are successful, the models and recommendations could be implemented more widely in their respective regions and potentially rolled out nationally, providing a standard for best practice. Mari Scheiffele, Oncology General Manager, Novartis UK & Ireland, said: "Our partnerships with the NHS are of paramount importance as we work towards our shared goal of improving treatment pathways and care for cancer patients. Pooling resources to identify areas for improvement and possible solutions helps to ensure patients receive the best possible outcomes."


The Independent Cancer Taskforce outlined their cancer strategy following on from the publication of the NHS Five Year Forward View, which identified a focus on improving outcomes across the whole cancer pathway[2],[4]. Initiatives such as these Joint Working Projects demonstrate Novartis' commitment to supporting this goal.

Novartis announced the launch of two new Joint Working Projects with National Cancer Vanguard sites, which aim to identify ways to improve cancer patient care pathways and access to services. The projects will be based at The Christie in Greater Manchester and within the UCLH Cancer Collaborative region (north and east London), covering a catchment population of 6.9 million people. The two projects are part of Novartis' ongoing commitment to combine resources, time, and expertise with the NHS, with the aim to significantly improve cancer patient outcomes.


With one in two people born after 1960 expected to develop cancer at some point in their lifetime[1], optimising working practices and addressing variations in care is essential to ensure the best outcomes for cancer patients. Central to both Joint Working Projects is the use of data analytics to generate insights, which will be used to improve cancer patients' experiences, one of the six key priorities of the NHS cancer strategy.


The Joint Working Project with UCLH Cancer Collaborative will adopt the use of Multi-Disciplinary Team (MDT) level balanced scorecards to capture service outcomes data for breast, lung, lymphoma, melanoma, and prostate cancer patient pathways. This service level data will include information on cancer patients' waiting times versus targets, the number of patients diagnosed with cancer, and the proportion of patients being prescribed chemotherapy and receiving it at home. Patient or clinical information will not be disclosed as part of the project.


Decisions on clinical practice are informed by data, however, information from these pathways is not currently captured under one source, and varies across different types of cancer and hospitals. The NHS and Novartis are jointly funding two project analysts to manage the project and to compare data from the MDT scorecards to service standards in the National Institute for Health and Care Excellence (NICE) treatment guidelines. Insights will be used by staff to improve MDTs' effectiveness and enhance patient care pathways, to develop care levels that are tailored to individual patient needs and provide a better quality of service for patients.
"Through the use of the MDT scorecards, we will be able to gather data on service outcomes across multiple cancers to identify areas for improvement," said Professor Kathy Pritchard-Jones, chief medical officer for UCLH Cancer Collaborative. "Reducing variations in cancer treatment pathways is vital to ensuring our patients receive the highest level of care we can provide them, regardless of the staging or type of cancer they have."


The Joint Working Project with The Christie NHS Foundation Trust will work to address care pathway inconsistencies in breast cancer, the most common cancer in the UK accounting for 31% of all new cancer diagnoses in women[3]. The project includes a partnership with IQVIA, a leading global provider of information and innovative technology solutions, to analyse current breast cancer pathways and identify opportunities to enhance care. This will involve examining relevant anonymised healthcare data including Public Health England's Cancer Analysis System (CAS) and NHS Hospital Episodic Statistics (HES) to establish the current state of the breast cancer treatment pathways across Greater Manchester so that variations in access to care can be better understood. The project will also evaluate patient journeys by enabling patients to record their experiences of treatment pathways through the use of innovative technology provided by the app, uMotif. It is anticipated that findings from the project will lead to improvements in the timeliness of treatment interventions for patients, and provide clarity on where to focus resource efforts, subsequently helping to address any variation in access to treatment.


"At The Christie we are committed to improving treatments and pathways for our patients, and this partnership will allow us to harness the power of data analytics to improve care for patients with secondary breast cancer," said Professor Andrew Wardley, clinical director of NIHR Manchester Clinical Research Facility at The Christie. "We are hopeful that the success in this project could lead to advancements in care for breast cancer patients across the country."


If the two initiatives are successful, the models and recommendations could be implemented more widely in their respective regions and potentially rolled out nationally, providing a standard for best practice. Mari Scheiffele, Oncology General Manager, Novartis UK & Ireland, said: "Our partnerships with the NHS are of paramount importance as we work towards our shared goal of improving treatment pathways and care for cancer patients. Pooling resources to identify areas for improvement and possible solutions helps to ensure patients receive the best possible outcomes."


The Independent Cancer Taskforce outlined their cancer strategy following on from the publication of the NHS Five Year Forward View, which identified a focus on improving outcomes across the whole cancer pathway[2],[4]. Initiatives such as these Joint Working Projects demonstrate Novartis' commitment to supporting this goal.

INVICTUS MD STRATEGIES CORP. is pleased to announce that , Gene Simmons, Chief Evangelist Officer for the company and its management team opened the trading day at the TSX Venture Exchange (TSXV). The appearance coincides with the company changing its share ticker from IMH to GENE.

"To have a cannabis company like Invictus open the trading at TSXV, one of the world's best trading communities, is truly inspiring," said Invictus Chairman and CEO Dan Kriznic. "With our footprint in Ontario and Alberta on track for full production over the next 12 months, and poised to help supply Canada's dynamic consumer marketplace with a wide variety of strains and extracts."

Invictus changed its TSX Venture symbol from IMH to GENE, effective immediately for trading commencing on March 20, 2018, to reflect the importance of the company's new partnership with rock icon and branding genius Gene Simmons, anticipating that Simmons will play a vital role as the company marches into this historic year for Canada and cannabis.

Simmons will be involved on a variety of different areas. His key focus will be on helping the company forge its public awareness strategy. Additionally, he will make appearances at the annual general meeting, investor meetings, and trade shows, and will serve as a media spokesperson. His efforts will be performed in accordance with the strict regulations of Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR), the Food and Drugs Act (FDA) and the Narcotic Control Regulations (NCR).

Simmons explored a number of potential cannabis partnerships before deciding to work with Invictus.
"As I learned more about the changing sentiment of the public and investors, I was enthusiastic to invest in the Cannabis space. I did my due diligence with the available information on the top 10 Licensed Cannabis Producers in Canada, including a number of face-to-face interviews," said Simmons. "They have a leadership that has the potential to change that and a solid plan for growth."

Sarepta Therapeutics, Inc , a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases.

Bristol-Myers Squibb Company and Pfizer Inc. will present findings from a real-world data (RWD) analysis titled, Comparison of Effectiveness, Safety, and the Net Clinical Outcome between Different Direct Oral Anticoagulants in 162,707 Non-Valvular Atrial Fibrillation Patients Treated in US Clinical Practice.

Nanologica AB (publ) has entered into a service agreement with global contract development and manufacturing organisation (CDMO) Sterling Pharma Solutions for the large-scale production of silica particles. 

Cell-based assays have become an important application in the life science sector, from basic to top-level research. They are widely used in biotech companies and academic research institutions to monitor cell health in real-time.

Bio-Techne has released MimEX™ GI, a new product line for generating 3-dimensional (3-D) gastrointestinal tissue on a 2-D surface.

Abbott announced the U.S. FDA approved the Masters HP™ 15mm rotatable mechanical heart valve, the world's smallest mechanical heart valve, that will allow doctors to treat babies and toddlers in need of a mitral or aortic valve replacement.

Globally, about 800 women die every day of preventable causes related to pregnancy and childbirth; 20 per cent of these women are from India,1 and Postpartum Haemorrhage (PPH) is the leading cause of maternal mortality in India.

Roche announced that the European Commission has approved Hemlibra® (emicizumab) for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors.

Recipharm, the contract development and manufacturing organisation (CDMO), has signed a licensing agreement with Altus Formulation Inc., a Canadian drug development company, to allow its customers to access new drug delivery technologies and products.

Eli Lilly and Company announced that the U.S. FDA has approved Verzenio™ in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.

Novo Nordisk announced the submission of a Biologics License Applications (BLA) to the US FDA and a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for N8-GP, an extended half-life factor VIII for treatment of people with haemophilia A.

RBC analyst Brian Abrahams said the decision will have "zero material impact" on Biogen as Zinbryta was expected to bring in about $400 million in 2027 revenue for the company, or less than 3% of total sales.

Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted positive opinions recommending that two Pfizer hematology medicines be granted marketing authorizations in the European Union (EU).

As global interest in traditional and alternative medicine grows, Elsevier, the global information analytics business specializing in science and health, announced that it is working with Beijing University of Chinese Medicine (BUCM) to create a new taxonomy for traditional Chinese medicine (TCM) in Embase, the world’s most comprehensive biomedical literature database.

Semiconductor wafer fabrication plants and ultra-high purity chemical suppliers can now strengthen their monitoring of trace elements within challenging sample matrices with a new triple quadrupole inductively coupled plasma mass spectrometer (ICP-MS), offering sub-parts-per-trillion detection—making it an ideal solution for ultraclean applications.

Contract development and manufacturing organisation (CDMO) Saneca Pharma has renewed an agreement with Pharmascience Inc, one of Canada’s largest pharmaceutical companies, for the manufacture and supply of prescription medicines in tablet form.

Founded in 1884, Victorinox is global company offering a series of innovative, functional and superior-quality products which reflect the company's timeless Swiss values.The iconic Swiss Army Knife is Victorinox's core product and is manufactured at its facility in Ibach, Switzerland.

CRF Health, the leading provider of patient-centered eSource for the life sciences industry, announced that its TrialConsent® electronic informed consent solution has been shortlisted for the ‘Best Patient-Focused Technological Development’ category in the 2018 Clinical & Research Excellence (CARE) Awards.

Despite significant technological advances in technology, cardiovascular diseases (CVDs) remain the number one cause of death globally. CVDs are a group of disorders of both the heart and blood vessels that can lead to heart attacks and strokes.

Alma Lasers, a subsidiary of Sisram Medical Ltd , the leading global innovator of laser light-based, radio frequency and ultrasound solutions for the aesthetic and surgical markets and the #1 rated leading provider of energy-based surgical and medical aesthetic solutions in the Peoples Republic of China announced the launch of the Soprano ICE Platinum.

On average, 1 in 10 children who enroll in pediatric phase I cancer trials are improved after the trial, and 1 in 50 die from drug-related complications, according to a new systematic review and meta-analysis published this week in PLOS Medicineby Jonathan Kimmelman from McGill University, Canada, and colleagues.

Allergan plc, a leading global pharmaceutical company, and Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, today announced that the U.S. FDA has accepted for filing Medicines360's supplemental New Drug Application (sNDA).

AbbVie , a global biopharmaceutical company, and Voyager Therapeutics, Inc. , a clinical-stage gene therapy company announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases.

AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US FDA has approved Imfinzi for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT).

The meeting will be held at the San Diego Convention Center and the scheduled times (noted in local Pacific Time) for the Allergan presentations, titles and authors are as follows:

Amgen announced that the Oncologic Drugs Advisory Committee of the U.S. FDA will review data supporting the BLINCYTO® (blinatumomab) supplemental Biologics License Application (sBLA) for the treatment of patients with minimal residual disease (MRD)-positive B-cell precursor acute lymphoblastic leukemia (ALL) at a meeting on March 7, 2018.

AbbVie  a global research and development-based biopharmaceutical company, today announced it will present new, late-breaking data across investigational medicines and HUMIRA® (adalimumab) at the 2018 American Academy of Dermatology (AAD) Annual Meeting (February 16-20, San Diego).

GSK announced the expanded indication for Fluarix Tetra (Quadrivalent Influenza Vaccine) has been approved in Europe to include adults and now children from six months of age for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine.

GlaxoSmithKline plc and Innoviva, Inc. announced the submission of the landmark IMPACT data to the European Medicines Agency as part of a type II variation to support an expanded label for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI’) in Europe for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (for the relief of symptoms and reduction of exacerbations, see section 5.1).

Vertex Pharmaceuticals Incorporated announced that the U.S. FDA approved Symdeko (tezacaftor/ivacaftor and ivacaftor) for treating the underlying cause of cystic fibrosis (CF) in people ages 12 and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or who have at least one mutation that is responsive to tezacaftor/ivacaftor.

The U.S. FDA approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant).

CRF Health, a leading global provider of patient-centered eSource technology and service solutions for the life sciences industry, announced that its electronic informed consent solution, TrialConsent®, has won the 2018 Best Practices Award at this year’s Clinical Informatics News Awards.

TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better
patient outcomes, today announced financial and company results for the fourth quarter and  full year of 2017.

CRF Health, a leading global provider of patient-centered eSource technology and service solutions for the life sciences industry, has announced the appointment of Bill Byrom as Vice President of Product Strategy & Innovation.

Lonza announced the latest addition to its cell-culture product portfolio – the Quasi Vivo® System. The Quasi Vivo® Device consists of an advanced, interconnected fluidics system to create more physiologically relevant cell-culture conditions, helping researchers improve the predictive value of their studies.

The Children’s Emergency Hospital "Louis Turcanu" brings over 90,000 patients in the Timișoara area to the PRS network of hospitals, expanding Clinerion’s global footprint into Romania.

Pharmapack Europe (#PharmapackEU), organised by UBM, announced the winners of the much celebrated 2018 Pharmapack Awards. Due to the outstanding quality of entries, six worthy winners were chosen across two categories, ‘Exhibitor Innovation’ and ‘Health Products’.

In an event at its new branch office attended by key customers and business associates, Vetter’s senior management representatives presented the company’s service portfolio along with its growth strategy for South Korea and the Asia Pacific (APAC) region.

Cobra Biologics (Cobra), an international contract development and manufacturing organisation (CDMO) of biologics and pharmaceuticals, and Symbiosis Pharmaceutical Services (Symbiosis), a contract manufacturing organisation (CMO) specialising in sterile Fill Finish, announced that they have been awarded a 16-month collaborative grant of £1.9m from Innovate UK.

Novartis AG announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US FDA approval of its NDA for Lutathera® (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors, in adults.

During the Society of Toxicology Meeting from 11-15 March 2018 at the Henry B. González Convention Center in San Antonio, TX (USA), Lonza will present two posters highlighting its latest research into developing more physiologically relevant in vitro cell-culture models for ADME-Tox testing.

UPM Raflatac's pharmaceutical and healthcare labeling experts will be present at Pharmapack exhibition on 7-8 February 2018 in Paris, France.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok